- 8, The Green Suite, 12341 Dover,
DE 19901-3618 - info@immgenuity.com
+1-302-321-5844
Immgenuity Inc.
Applying ingenuity and innovation
to improve lives around the world
News, in Reverse Chronological Order
- August 2023Immgenuity has entered into a research collaboration agreement with Biostax Corp. Biostax Corp. is a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a well-defined path to market. By utilizing a biotech portfolio hub-and-spoke engine, the company plans to advance focused and efficient small-scale biotechnology and pharmaceutical programs through subsidiaries, investment vehicles, or partnerships, and deploy its products from those programs in markets both in the U.S. and internationally for initial commercialization. The joint research will be focused on using Immgenuity's IMTV014 and Biostax's Lodonol® independent and together to determine if the immune modulatory effects of Lodonol® are synergistic with IMTV014. READ PRESS RELEASE
- August 2023Immgenuity's abstract on targeting Nef protein to induce remission in HIV patients has been accepted for a poster and oral presentatin at the HIV Cure Symposium, organized by the HIV Cure Center at University of Ghent in Belgium. This presitgious conference attracts HIV Cure experts from around the world where different strategies are explored and discussed. The meeting has top experts such as Dr. Francesco Simonetti from Johns Hopkins University, Dr. Steve Deeks from UCSF and Dr. Eli Boritz from NIH among others. READ PRESS RELEASE
- August 2023Senator George Allen has had a distinguished career in local, state and federal governments. He served in the Virginia house of delegates from 1983 to 1991. In 1993, he was elected Governor of Virgina until 1998. As governor, he was the architect of a bipartisan welfare reform bill. He was also the prime mover behind "Truth in Sentencing Act" which passed both houses with overwhelming majorities. He was also a visionary in a SOLS program (Standards of Learning), supported enthusiastically by the American Federation of Teachers. The SOLS program was visionary in its emphasis on core subjects - way before anyone thought of STEM. From 1998 to 2000, Senator Allen became a partner in the law firm McGuire Woods LLP. He also served on the boards of Commonwealth Biotechnologies, Xybernaut and Com-Net Ericsson. In 2000, he was elected to the US Senate. In the senate, he served on the Foreign Relations, Energy and Natural Resources, and Commerce, Science and Transportation Committees. His landmark accomplishment was the 21st Century Nanotechnology Research and Development Act. For Immgenuity, Sen. Allen will be able to use his distinguished legal, administration and legislative skills to help the company have excellent corporate governance and help the company fulfill its strategic vision. As Immgenuity tries to seek a congressional consensus for its research, Sen. Allen will be a powerful voice on the Capitol Hill to promote research on Immgenuity's IMTV014. READ PRESS RELEASE
- July 2023Immgenuity shall be presenting its HIV immunotherapy at the US Conference on HIV AIDS (USCHA) to be held in Washington, DC in September 2023. The USCHA Conference is a renowned gathering of scientists, researchers, and US Government officials involved in HIV-AIDS issues and budgets. The conference provides a platform for sharing the latest scientific advancements, clinical trials, and breakthroughs in the field of HIV/AIDS. In addition to the formal presentation, the company leadership will be meeting congressional representatives, White House President's Advisory Council on HIV/AIDS (PACHA) and NIH program directors. READ PRESS RELEASE
- July 2023Maj. General (Retd) Kevin Leonard joined Immgenuity's Board of Directors. Maj. Gen. (Retd) Kevin Leonard, is a former senior vice president of contingency operations at Vectrus (NYSE: VEC) and a former president and CEO Charleston, South Carolina-based military logistics services provider Technica. Gen. Leonard led the Military Surface Deployment Distribution Command, where he was responsible for deployment and distribution work across expeditionary missions, before he concluded his 33-year military career. His private sector career also includes leadership roles at Fluor (NYSE: FLR) and Amazon (NYSE: AMZN). The National Defense Industrial Association recognized Leonard with its Logistician Emeritus Award in 2014 for his significant contributions to the U.S. military’s logistical operations. For Immgenuity, Gen. Leonard will be instrumental in starting a conversation with and developing a relationship with Military HIV Research Program (MHRP) and Military Infectious Diseases Research Program (MIDRP.) Gen. Leonard has led his life and military as well as civilian career with the principles of integrity, respect and responsibility and his leadership skills both in and off the service will be invaluable to Immgenuity, Inc. As Immgenuity tries to seek a congressional consensus for its research, Gen. Leonard will be a powerful voice on the Capitol Hill to promote research on Immgenuity's IMTV014. READ PRESS RELEASE
- May 2023Lydie Trautmann, EngD, PhD has joined IMmgenuity's Scientific Advisory Board. Dr. Trautmann is Director of Translational Research, Global Infectious Diseases Portfolio, at the Henry M Jackson Foundation (HJF) for the Advancement of Military Medicine in support of Military HIV Research Program (MHRP), Emerging Infectious Diseases Branch at Walter Reed Medical Center (EIDB), and the Diagnostics and Countermeasures Branch (DCB.) She oversees the research efforts in the current and upcoming MHRP clinical trials in Thailand. Dr. Trautmann received her M.Sc. in Cell and Molecular Biology and Doctor of Engineering degrees in 1998 from Louis Pasteur University, and her Ph.D. in Immunology at Paris V University - René Descartes in 2003. Prior to her role at HJF, she performed research for two decades in translational human immunology evaluating early treatment, HIV-associated neurocognition and immune interventions aimed at achieving HIV remission at the Vaccine and Gene Therapy Institute in Florida and at the Oregon Health and Science University as well as at MHRP. She has established a strong research agenda with high ranked publications, a large collaborative network and a vigorous funding portfolio. She also serves on several national and international review committees. Dr. Trautmann’s lab is currently focused on HIV functional cure studies. She says understanding the complexity of acute HIV infection is key to creating a viable vaccine. She and her team are working to define the impact of treatment initiation in acute infection and the quality of the immune memory response. By researching whether the memory response is better in the extremely early, middle, or late stages of acute infection, Dr. Trautmann and her team hope to provide crucial insight into immunology which could elevate vaccine development.The lab also studies the immunology of efficacious vaccines against diseases like yellow fever, to provide insights into how to create a viable HIV vaccine. READ PRESS RELEASE
- May 2023Immgenuity shall be presenting its HIV immunotherapy at the Italian Conference on AIDS and Antiretroviral Research (ICAR) to be held in Bari, Italy in June 2023. The ICAR Conference is a renowned international gathering of scientists, researchers, and experts in the field of HIV research and therapy. The conference provides a platform for sharing the latest scientific advancements, clinical trials, and breakthroughs in the field of HIV/AIDS. READ PRESS RELEASE
- May 2023Jesse Milan, Jr., JD has joined IMmgenuity's Scientific Advisory Board in his individual capacity. Jesse Milan, Jr., JD is a tireless community advocate and recognized national and international expert on HIV/AIDS policies and programs. Mr. Milan brings over 30 years in executive roles in public and private sectors, including in government, not-for-profit, academic, and faith organizations. During his long career, Mr. Milan has directed multi-million-dollar budgets and programs for federal, state, local, and global health agencies. Mr. Milan’s exceptional record of public service includes serving currently on the Scientific Advisory Board for the President’s Emergency Plan for AIDS Relief (PEPFAR), on the Infectious Disease Board of the American Board of Internal Medicine, and on the board of AVAC (AIDS Vaccine Advocacy Coalition). He is an officer of the board of directors of Funders Concerned About AIDS (FCAA) and serves on the Dean’s Advisory Council for the UNC Gillings School of Global Public Health. Mr. Milan's advice and guidance will be his own and he will not be acting on behalf of or as a representative of any organization. READ PRESS RELEASE
- April 2023Dr. Jessica Robinson-Papp, MD, MS has joined our Scientific Advisory Board. Dr. Robinson-Papp is a highly accomplished neurologist and clinical researcher with extensive experience in the development of novel treatments for neurological diseases. She currently serves as the Vice Chair for Clinical Research and Professor of Neurology at the Icahn School of Medicine at Mount Sinai Hospital in New York City. Dr. Robinson-Papp has published over 70 peer-reviewed articles, reviews, editorials and book chapters in top-tier medical journals. She has also served as the principal investigator for numerous clinical trials investigating the safety and efficacy of new treatments for neurological disorders, including multiple sclerosis and peripheral neuropathy. READ PRESS RELEASE
- April 2023Dr. Ron Sekura has joined our Scientific Advisory Board. Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). His expertise with regulatory affairs relating to biologicals such as Immgenuity's IMTV014 shall be invaluable as we move forward into manufacturing, IND submission to the FDA and beyond. READ PRESS RELEASE
- March 2023Dr. Daniel Kuritzkes has joined our Scientific Advisory Board. Dr. Kuritzkes is the Chief of Infectious Diseases at Harvard's Brigham and Women's Hospital and Massachusetts General Hospital. His contributions to HIV research have been salient and well-known. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance and HIV eradication. Dr. Kuritzkes has authored or co-authored over 650 publications in peer-reviewed journals. READ PRESS RELEASE
- February 2023Dr. Jürgen Rockstroh, MD joins our Scientific Advisory Board. Dr. Rockstroh is an eminent HIV scholar with over 700 publications in peer-reviewed journals and an author of several book chapters. From 2007-2011 he was elected as the president of the German AIDS Society. Since 2009, he is a member of the executive committee of the European AIDS Clinical Society (EACS) and from 2011-2020 member of the governing council of the International AIDS Society. He also was the chair of the National German AIDS Advisory Panel from 2011-2017 and the EACS coinfection guidelines from 2008-2017. In 2015 Professor Rockstroh was elected chair of HIV in Europe (in 2019 renamed as EuroTEST. Dr. Rockstroh's expertise will assist the company to plot a robust clinical trials strategy as well as its wide acceptance in the community. READ PRESS RELEASE
- February 2023Immgenuity signed a collaboration agreement with Oregon Health and Sciences University (OHSU). Under the leadership of Dr. Marcel Curlin, a specialist in HIV and an Associate Professor, Immgenuity will be able to work with OHSU's Jungers Center for Neuroscience Research and the Vollum Institute which does basic science neurobiology research. Immgenuity plans to apply for NIH grants to develop a clinical, fMRI and serology to diagnose HAND and monitor progress in patients. READ PRESS RELEASE
- January 2023Immgenuity leadership will be attending the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) conference to be held in Copenhagen, Denmark in April 2023. Company's leadership will be attending this conference to further introduce company's approach to treat HAND and HIV to the HIV research community.
- January 2023Immgenuity submitted an abstract to International Symposium on HIV and Emerging Infectious Diseases (ISHIED) to be held in Avignon, France in May. The abstract, when accepted, will bring further awareness of company's product and its novel mechanism of action to the world HIV scientists. Company's leadership will be attending this conference to further introduce company's approach to treat HAND and HIV to the HIV research community.
- January 2023Immgenuity submitted an abstract to International AIDS Society Science Conference to be held in Brisbane, Australia in July. The abstract, when accepted, will bring further awareness of company's product and its novel mechanism of action to the world HIV scientists. Company's leadership will be attending this conference to further introduce company's approach to treat HAND and HIV to the HIV research community.
- January 2023Dr. Richard Ogden joined Immgenuity's Board of Directors AND the Scientific Advisory Board. Dr. Ogden, who was a senior executive at Agouron and Pfizer was also the force behind research and FDA approval of nelfinavir (Viracept®) a protease inhibitor. He brings his unique expertise in both corporate governance and HIV science to Immgenuity. READ PRESS RELEASE
- January 2023Dr. Carol Brosgart, a well-respected HIV researcher in the battle against HIV from the beginning and she is a Clinical Professor of Medicine, Biostatistics and Immunology at University of California, San Francisco. She serves as a board member and advisor to various institutions, most notably the San Francisco AIDS foundation. READ PRESS RELEASE
- December 2022Dean Petkanas joined Immgenuity's Board of Directors. Mr. Petkanas brings his 20+ years of experience in drug development, the FDA process as well as his expertise in capital markets to our company. His addition would solidify our corporate governance as well as the execution of our strategy. READ PRESS RELEASE
- December 2022Immgenuity leadership attended HIV-DART conference in Cabo San Lucas. Immgenuity had a poster presentation at the conference which was well-received. The leadership was also able to discuss the company's strategy and rationale with several key opinion leaders including Prof. Raymond Schinazi of Emory University and a prolific inventor of several key pharmaceuticals. READ PRESS RELEASE
- November 2022Immgenuity's abstract submitted to HIV-DART conference was accepted. The company can now showcase its novel therapeutic vaccine to conference attendees which includes several leading HIV researchers and key opinion leaders.
- October 2022Marcel Curlin, MD, joined Immgenuity's Scientific Advisory Board. Dr. Curlin is an Associate Professor of Medicine at Oregon Health and Science University in Portland, Oregon. Dr. Curlin co-directs development of infectious diseases research collaborations in Southeast Asia for OHSU Global, and is clinically active on the Infectious Diseases Inpatient consultation service. Dr. Curlin has experience in both clinical and laboratory-based research in HIV. Dr. Curlin research focuses on HIV vaccine development, HIV prevention methods, and basic mechanisms of host-virus interactions during HIV infection. READ PRESS RELEASE
- October 2022Immgenuity leadership attended the US Conference on HIV and AIDS (USCHA) held in San Juan, Puerto Rico. The leadership met with Ms. Marlene McNeely, co-chair of President's Advisory Council on HIV and AIDS (PACHA). The company was able to set a dialog in motion to get White House support for the emergin and serious issue of HAND with respect to company's novel strategy. A future presentation to PACHA was discussed. The leadership also met with a program director at National Institutes of Health, Dr. Michael Stirrat and briefed him on the issue of HAND and company's novel therapy. In the same meeting, the leadership introduced the issue of HAND and the company's approach to Dr. Maureen Goodnow who is the Director of AIDS Research at NIH.
- September 2022Dr. Satish Chandran joined Immgenuity's Scientific Advisory Board. In addition to being a prolific researcher and an executive at several life sciences companies, Dr. Chandran was the VP of vaccine manufacturing at Wyeth and Pfizer, bringing his epecial expertise in large scale vaccine manufacturing to benefit the company. READ PRESS RELEASE
- September 2022Kevin Phelps, CPA joined Immgenuity's Board of Directors. Mr. Phelps has a long experience in corporate governance starting with Kodak and he has been a veteran of several life sciences company boards, being a director of Oyagen, AREV life science and Immune Therapeutics among others. The company is excited to have Mr. Phelps' leadership in management, governance, guidance for execution and especially his expertise in capital markets. READ PRESS RELEASE
- August 2022Dr. Roscoe M. Moore joined Immgenuity's Scientific Advisory Board. Dr. Mooore is a former Assistant Surgeon Genera of the United States and is well-known in the research, government and life-sciences community. He is on many notable boards, of particular interest being the Institute of Human Virology in Baltimore, Maryland led by Dr. Robert C. Gallo. READ PRESS RELEASE
- August 2022Immgenuity's leadership filed the Rapporteur Report with Congressman Adriano Espaillat (D-NY) and severa discussions were held about various gaps in HIV care. Our goal of requiring funding for HAND and a live-attenuated therapeutic vaccine was forcefully represented to the Congressman and through him to the Congressional HIV Caucus. It is anticipated that a funding bill encompassing various heretofore inconspicuous areas would get attention.
- July-August 2022Immgenuity's leadership attended the World AIDS Conference held in Montréal, Canada. Initial dialog wsa started with many notable researchers such as Dr. Dan Kuritzkes, Dr. Peter Hunt and Dr. Linda Gail Bekker. The leadership also met with Ms. Marsha Martin, executive at President's Advisory Council for HIV and AIDS (PACHA) and Dr. Stuart Shapiro, Director of NIAID's HIV vaccine program. A brief meeting was held with Dr. Roberto Corales, a program director for Gilead Sciences and Mr. Jon Cohen, a reporter for Science magazine who needs no introduction as the author of the most authoritative book on HIV Vaccine develoment.The company leadership was also invited to be Rapporteurs for Congressman Adriano Espaillat (D-NY) and commenced writing the rapporteur report.
- July 2022Immgenuity was formed with a goal to bring an IND ready HIV therapeutic vaccine to market. The company wants to move this project forward rapidly by attending most upcoming conferences, creating awareness in both the scientific and lay stakeholders in HIV. The company will present its science to leading researchers and build a concensus around the company's novel therapeutic vaccine by presenting and networking with leading researchers and government officials in the field.